Prevalence of Bloodstream Pathogens Is Higher in Neonatal Encephalopathy Cases vs. Controls Using a Novel Panel of Real-Time PCR Assays



Cally J. Tann^{1,5}*, Peter Nkurunziza², Margaret Nakakeeto⁵, James Oweka², Jennifer J. Kurinczuk⁶, Jackson Were², Natasha Nyombi⁵, Peter Hughes³, Barbara A. Willey¹, Alison M. Elliott^{1,2}, Nicola J. Robertson³, Nigel Klein^{4,7}, Kathryn A. Harris^{4,7}

1 Clinical Research Department, Faculty of Infectious & Tropical Diseases, London School of Hygiene & Tropical Medicine, London, United Kingdom, 2 MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda, 3 Institute for Women's Health, University College London, Medical School Building, London, United Kingdom, 4 Institute for Child Health, University College London, London, United Kingdom, 5 Mulago University Hospital, Kampala, Uganda, 6 National Perinatal Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom, 7 Department of Microbiology, Virology and Infection Control, Great Ormond Street Hospital for Children, London, United Kingdom

Abstract

Background: In neonatal encephalopathy (NE), infectious co-morbidity is difficult to diagnose accurately, but may increase the vulnerability of the developing brain to hypoxia-ischemia. We developed a novel panel of species-specific real-time PCR assays to identify bloodstream pathogens amongst newborns with and without NE in Uganda.

Methodology: Multiplex real-time PCR assays for important neonatal bloodstream pathogens (gram positive and gram negative bacteria, cytomegalovirus (CMV), herpes simplex virus(HSV) and *P*. falciparum) were performed on whole blood taken from 202 encephalopathic and 101 control infants. Automated blood culture (BACTEC) was performed for all cases and unwell controls.

Principal Findings: Prevalence of pathogenic bacterial species amongst infants with NE was 3.6%, 6.9% and 8.9%, with culture, PCR and both tests in combination, respectively. More encephalopathic infants than controls had pathogenic bacterial species detected (8.9%vs2.0%, p = 0.028) using culture and PCR in combination. PCR detected bacteremia in 11 culture negative encephalopathic infants (3 Group B Streptococcus, 1 Group A Streptococcus, 1 *Staphylococcus aureus* and 6 Enterobacteriacae). Coagulase negative staphylococcus, frequently detected by PCR amongst case and control infants, was considered a contaminant. Prevalence of CMV, HSV and malaria amongst cases was low (1.5%, 0.5% and 0.5%, respectively).

Conclusion/Significance: This real-time PCR panel detected more bacteremia than culture alone and provides a novel tool for detection of neonatal bloodstream pathogens that may be applied across a range of clinical situations and settings. Significantly more encephalopathic infants than controls had pathogenic bacterial species detected suggesting that infection may be an important risk factor for NE in this setting.

Citation: Tann CJ, Nkurunziza P, Nakakeeto M, Oweka J, Kurinczuk JJ, et al. (2014) Prevalence of Bloodstream Pathogens Is Higher in Neonatal Encephalopathy Cases vs. Controls Using a Novel Panel of Real-Time PCR Assays. PLoS ONE 9(5): e97259. doi:10.1371/journal.pone.0097259

Editor: Sudha Chaturvedi, Wadsworth Center, United States of America

Received February 14, 2014; Accepted April 14, 2014; Published May 16, 2014

Copyright: © 2014 Tann et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the Wellcome Trust through the London School of Hygiene & Tropical Medicine Clinical PhD programme [grant 094016/Z/ 10/Z to CT]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: cally.tann@lshtm.ac.uk

Introduction

Identification of bloodstream infections in newborns, either alone or as a co-morbidity amongst infants affected by conditions such as neonatal encephalopathy (NE), is problematic. Clinical signs associated with neonatal sepsis syndrome, such as lethargy, poor feeding and convulsions, overlap substantially with other conditions such as NE. In preclinical studies exposure to bacterial endotoxin has been shown to increase vulnerability of the developing brain to perinatal hypoxia-ischemia [1–3]. However, clinical studies have yet to precisely define the relationship between perinatal infections and neonatal encephalopathy (NE). Fetal exposure to inflammation and, or, infection has also been found to increase brain vulnerability to hypoxia-ischemia via stimulation of toll-like receptors, immune and inflammatory responses, chemotaxis and cell death[4–6]. If implicated, the high prevalence of perinatal infections in the African setting means the contribution to the etiology of NE may be substantial.

The use of pediatric blood culture techniques in the neonatal period is complicated by low circulating bacterial load, the small volumes of blood taken, and because intrapartum antibiotics may render bacteria non-viable. Open techniques for taking neonatal blood samples increase the risk of contamination with commensal organisms making interpretation of results problematic. In

isitivities and sequences for the Real-Time PCR assays.
Fable 1. Primer and probe target genes, se

State Nylococcus coafennatic Sabet 2006 coafennatic Site action coafennatic	Ibet 2006 coa-forward: 5'-GTAGATTGGGGCAATTACATTTGGAGG Mix 1: IX QuantFast Multiplex PCR masternix (I 0.15 µM each of GAS-forward, coa-reverse and co 0.3 µM each of GAS-forward, coa-reverse, 0.2 0.0 JµM each of GAS-forward, PC-reverse, 0.1 µM each of PC-forward, PC-reverse, 0.2 probe, 0.1 µM each of PC-forward, PC-forward, PC-reverse, 1.6 probe, 0.1 µM each of PC-forward, S'-JGEAGFGAGFGACTATATTGTTAACC-BHQ1 probe, S'-JOE- CGGTGGAGFGAGFGACTATATTGTTAACC-BHQ1 probe, S'-JOE- CGGTGAGFGAGFGACTATATTGTTAACC-BHQ1 probeward, S'-JOE- CGGTGAGFGAGFGACTATATTGTTAACC-BHQ1 probeward, S'-JOE- CGGTGAGFGAGFGACTATATTGTTAACC-BHQ1 probeward, S'-GGACGAGFGAGFGAGFGAGFGAGFGAGFGAGFGAGFGAGF
Streptococcus csnf 0.1-1 cfu/reaction This study Coarteverse: 5'- Streptococcus csnf 0.1-1 cfu/reaction This study CAS-forward: 5'- pogenes Anus non-coding NA This study CAS-forward: 5'- Internal Mus non-coding NA This study PC-forward: 5'- Positive sequencing NA Out-1 cfu/reaction Haris et al 2008 Streptococcus Mus non-coding NA Out-1 cfu/reaction Haris et al 2008 Streptococcus Mus non-coding Out-1 cfu/reaction Harris et al 2008 Hyt-forward: 5'- Streptococcus Streptococcus Streptococcus Streptococcus Streptococcus Harris et al 2008 Hyt-forward: 5'- Streptococcus Streptococcus Streptococcus Streptococcus Streptococcus Harris et al 2008 Streptococcus	coa-reverse: 5'-CGCATCTGCTTTGTTATCCCATGTA coa-probe: 5'FAM- TAGGCGCATTGCCATGTA doa-probe: 5'FAM- TAGGCGCATTGCCATGTA doa-probe: 5'-TGGATGTGCAGGTTGCAGGTTAGAC GAS-reverse: 5'-JOE- CGGTGCAGGTATATTGTTAACC-BHQ1 GAS-probe: 5'-JOE- CGGTGCAGCACTATATTGTTAAACC-BHQ1 IPC-forward: 5'-GGACGACTATATTGTTAAACC-BHQ1
Streptococcus CoR O.1-1 cfu/reaction This study CoR-forward: 5'- GAS-forward: 5'- GAS-probe: 5'-L httemal Mus non-coding NA This study PC-forward: 5'- GAS-probe: 5'-L httemal Mus non-coding NA This study PC-forward: 5'- GAS-probe: 5'-L positive sequencing NA This study PC-forward: 5'- GAS-probe: 5'-L positive aequencing NA This study PC-forward: 5'- GAS-probe: 5'-L positive aequencing NA DI-1 cfu/reaction Harris et al 2008 preproceccus sip 0.1-1 cfu/reaction Berseng et al 2007/ GBS-reverse: 5'- GBS-reverse: 5'- GBS-reverse: 5'- GBS-reverse: 5'- family tetrerobacteriaceae dnd 1-10 cfu/reaction This study ent-forward: 5'- GBS-reverse: 5'- GBS-reverse: 5'- GBS-reverse: 5'- GBS-reverse: 5'- family	coa-probe: 5'FAM- TAGGCGCATTAGCAGTTGCATC-BHQ1 is study GAS-forward: 5'-TGGATGTGGTTGCAGGTTTAGAC GAS-reverse: 5'- CGGGCAAGTAGTTCTTCATGG GAS-probe: 5'-JOE- CGGTGCAGCAGTATTTGTTAACC-BHQ1 GAS-probe: 5'-JOE- CGGTGCAGCAGTATTTGTTAACC-BHQ1 IPC-forward: 5'-GGACAGTATTGTTAACC-BHQ1
Streptococcus csrR 0.1-1 cfu/reaction This study GAS-forward: 5'- pogenes Amateria Amateria GAS-probes 5'-0 Internal Mus non-coding NA This study PC-forward: 5'-0 Internal Mus non-coding NA This study PC-forward: 5'-0 Internal Mus non-coding NA This study PC-forward: 5'-0 Positive Process Process Process PC-forward: 5'-0 Positive Process Process Process Process Positive Process Process Process Process Process Process	iis study GAS-forward: 5'-TGGATGTGGTGGCAGGTTTAGAC GAS-reverse: 5'- CGGGCAAGTAGTTCTTCAATGG GAS-probe: 5'-JOE- CGGTGCAGGAGTATTGTTAAACC-BHQ1 GAS-probe: 5'-JOE- CGGTGCAGGAGCACTATTGTTAAACC-BHQ1 IPC-forward: 5'-GGACACTATGCCCTTAGA
Internal GAS-reverse: 5 ⁻¹ Internal Mus non-coding NA This study IPC-forward: 5 ⁻ -G Positive sequencing NA This study IPC-forward: 5 ⁻ -G Positive sequencing NA This study IPC-forward: 5 ⁻ -G Positive internal internal IPC-forward: 5 ⁻ -G Streptococcus jyth 0.1-1 cfu/reaction Harris et al 2008 Iyth-forward: 5 ⁻ -G Streptococcus sip 0.1-1 cfu/reaction Harris et al 2007 GBS-forward: 5 ⁻ -G Streptococcus sip 0.1-1 cfu/reaction Berseng et al 2007/ GBS-forward: 5 ⁻ -G GBS-reverses study interverses study eff-reverses study Streptococcus she 0.1-1 cfu/reaction Berseng et al 2007/ GBS-forward: 5 ⁻ -G GBS-reverses study interverses study eff-reverses study GBS-reverses study lerseng et al 2007/ GBS-reverses study eff-reverses study GBS-reverses interverses study lerseng study eff-reverses study <	GAS-reverse: 5'- C6G6CAAGTAGTTCTTCAATGG GAS-probe: 5'-JOE- C6GTGCAGGACGACTATATTGTTAAACC-BHQ1 his study IPC-forward: 5'-G6ACACTATGCCCCTCAGA
Internal Mus non-coding NA This study IPC-forward: 5'-G Positive control (IPC) Resenced IPC-forward: 5'-G Positive control (IPC) IPC-forward: 5'-G IPC-forward: 5'-G Streptococcus IytA 0.1-1 cfu/reaction Harris et al 2008 IytA-forward: 5'-G Streptococcus Sip 0.1-1 cfu/reaction Harris et al 2008 IytA-forward: 5'-G Streptococcus Sip 0.1-1 cfu/reaction Harris et al 2008 IytA-forward: 5'-G Streptococcus Sip 0.1-1 cfu/reaction Harris et al 2008 IytA-forward: 5'-G Streptococcus Sip 0.1-1 cfu/reaction Harris et al 2007/ GBS-forward: 5'-G Streptococcus Sip 0.1-1 cfu/reaction Harris et al 2007/ GBS-forward: 5'-G Streptococcus Sip 0.1-1 cfu/reaction Harris et al 2007/ GBS-forward: 5'-G Streptococcus Sip 0.1-1 cfu/reaction Harris et al 2007/ GBS-forward: 5'-G Briterobacteriacea And I-10 cfu/reaction Harris study GBS-forward: 5'-G Briterobacteriacea And I-10 cfu/reaction Harris study ent-forward: 5'-G	GAS-probe: 5'-JOE- CGGTGCAGACTATATTGTTAAACC-BHQ1 is study IPC-forward: 5'-GGACACTATGCCCCTCCTTAGA
Internal positive control (IPC) Mus non-coding sequencing sequencing NA This study IPC-forward: 5'- IPC-probe: 5'- IP	his study IPC-forward: 5'-GGACACTATGCCCCTCCTTAGA
IPC-reverse: 5'-A IPC-reverse: 5'-A Streptococcus JytA IPC-probe: 5'CyS pneumoniae JytA-forward: 5'- IPC-probe: 5'CyS Streptococcus sip 0.1-1 cfu/reaction Harris et al 2008 JytA-forward: 5'- Streptococcus sip 0.1-1 cfu/reaction Berseng et al 2007 GB5-forward: 5'- Streptococcus sip 0.1-1 cfu/reaction Berseng et al 2007 GB5-forward: 5'- GB5-reverse: 5' Probe this study GB5-forward: 5'- GB5-reverse: 5'- Enterobacteriaceae dnd 1-10 cfu/reaction This study ent-forward: 5'- Enterobacteriaceae dnd 1-10 cfu/reaction This study ent-forward: 5'-	
IPC-probe: 5'Cy5 Streptococcus IptA = 0.1-1 cfu/reaction Harris et al 2008 IptA-forward: 5'- pneumoniae NtA = 0.1-1 cfu/reaction Harris et al 2007 IptA-forward: 5'- Streptococcus sip 0.1-1 cfu/reaction Berseng et al 2007/ GB5-forward: 5'- Streptococcus sip 0.1-1 cfu/reaction Berseng et al 2007/ GB5-forward: 5'- Streptococcus sip 0.1-1 cfu/reaction Berseng et al 2007/ GB5-forward: 5'- GB5-reverse: 5' Enerobacteriaceae dndf Into cfu/reaction This study Enerobacteriaceae dndf 1-10 cfu/reaction This study ent-forward: 5'-J Enerobacteriaceae dndf 1-10 cfu/reaction This study ent-forward: 5'-J	IPC-reverse: 5'-AGCTCCAAACTCCGTCTCTGTAA
Streptococcus JytA JytA JytA JytA pneumoniae () () () () Streptococcus () () () () Streptococus () () () () Streptococus () () () () Streptococus () () () () Streptococus<	IPC-probe: 5'Cy5-TTGGGAACAAAACACCCATGGAAGGA-BHQ2
hyth-reverse: 5' - ' hyth-reverse: 5' - ' Streptococcus sip 0.1-1 cfu/reaction Berseng et al 2007/ GB5-forward: 5' - ' agalactiae Probe this study GB5-forward: 5' - ' GB5-reverse: 5' - ' GB5-reverse: 5' - ' Enterobacteriaceae dndK 1-10 cfu/reaction This study ent-forward: 5' - J Enterobacteriaceae dndK 1-10 cfu/reaction This study ent-forward: 5' - J Enterobacteriaceae dndK 1-10 cfu/reaction This study ent-forward: 5' - J Enterobacteriaceae dndK 1-10 cfu/reaction This study ent-forward: 5' - J	arris et al 2008 lytA-forward: 5'-ACGCAATCTAGCAGATGAAGC Mix 2 : 1X QuantiFast Multiplex PCR mastermix (C 0.2 µM each of lytA-forward, lytA-reverse, lytA-pro forward, GBS-reverse and GBS-probe, 7 µL extracte molecular grade water to give a final reaction vol 20 µL
Streptococcus sip 0.1–1 cfu/reaction Berseng et al 2007/ GBS-forward: 5'- GBS-reverse: 5'- agalactiae A A D D D D D Enterobacteriaceae And 1–10 cfu/reaction This study ent-forward: 5'- JC Enterobacteriaceae And 1–10 cfu/reaction This study ent-forward: 5'- JC	lytA-reverse: 5' - TGTTTGGTTGGTTATTCGTGC
Streptococcus sip 0.1–1 cfu/reaction Berseng et al 2007/ GBS-forward: 5'- GBS-reverse: 5'- agalactiae Amol 1–10 cfu/reaction This study ent-forward: 5'- GBS-probe: 5'-IC Enterobacteriaceae Amol 1–10 cfu/reaction This study ent-forward: 5'-A family ent-forward: 5'-A ent-forward: 5'-A ent-forward: 5'-A	lyta-probe: 5'FAM- TTTGCCGAAAACGCTTGATACAGGG-BHQ1
GBS-reverse: 5' - 'GBS-reverse: 5' - 'GBS-probe: 5' JC Enterobacteriaceae dnaK 1-10 cfu/reaction This study ent-forward: 5' - B family ent-forward: 5' - B ent-forward: 5' - B ent-forward: 5' - B	rseng et al 2007/ GBS-forward: 5'-ATCCTGAGACACCTGACA obe this study
GBS-probe: 5' JC Enterobacteriaceae dnaK 1-10 cfu/reaction This study ent-forward: 5'-A family family ent-reverse: 5'-G ent-reverse: 5'-G	GBS-reverse: 5'- TTGCTGGTGTTTCTATTTTCA
Enterobacteriaceae <i>dnaK</i> 1–10 cfu/reaction This study ent-forward: 5'- <i>h</i> family ent-forward: 5'-G	GBS-probe: 5' JOE- ATCAGAAGAGTCATACTGCYACTTC-BHQ1
ent-reverse: 5'-G	nis study ent-forward: 5'-ACCTGGGTACWACCAACTCTTGTGT Mix 3: 1X QuantiFast Multiplex PCR mastermix (C 0.25 µM each of ent-forward, ent-reverse and ent 0.1 µM each of tuf-forward, tuf-reverse and tuf-for extracted DNA and molecular grade water to giv reaction volume of 20 µl.
	ent-reverse: 5'-6TCACTGCCTGACGTTTAGC
ent-probe: 5'-JO	ent-probe: 5'-JOE-AGGATGGTGAAACTCTGGTWGGTCAGCC-BHQ1
Staphylococcus tuf 1–10 cfu/reaction This study tuf-forward: 5'-C species	nis study tuf-forward: 5'-CATTCCAACTCCAGAACGTGAYT
tuf-reverse: 5'-C/	tuf-reverse: 5'-CACGACCAGTGAATTACG
tuf-probe: 5'-CY	tuf-probe: 5'-CY5-TGAYAAACCATTCATGATGCCAGTTGAGG-BBQ

Table 1. Cont.					
Organism	Target gene	Assay sensitivity	Reference	Primer and probe sequences	Multiplex Reaction Mixtures
CMV	DNA polymerase	5 copies/reaction	This study	CMV-forward: 5'-GCATGCGCGAGTGTCAAGAC	Mix 4: 1X QuantiFast Multiplex PCR mastermix (Qiagen), 0.2 μM each of CMV-forward, CMV-reverse, CMV-probe, P. fal- forward, P. fal-reverse and P. fal-probe, 7 μl extracted DNA and molecular grade water to give a final reaction volume of 20 μl
				CMV-reverse: 5'-GTTACTTTGAGCGCCATCTGTTCCT	
				CMV-probe: 5'-CY5-TGCGCCGTATGCTGCTCGACA-BBQ	
Plasmodium falciparum	SSU RNA	<3parasites/ul	Adegnika et al 2006	PFal-forward: 5'-CCG ACT AGG TGT TGG ATG AAA GTG TTA A	
				Plas-reverse: 3'-AAC CCA AAG ACT TTG ATT TCT CAT AA	
				Pfal-probe: 5'- FAM-CTT TCG AGG TGA CTT TTA GAT-	
HSV 1 and 2	DNA polymerase	5 copies/reaction	This study	HSV-forward: 5'-GACAGCGAATTCGAGATGCTG	Mix 5:1 XQuantiFast Multiplex PCR mastermix (Qiagen), 0.4 μM each of HSV-forward and HSV-reverse, 0.2 μM each of HSV-1-probe and HSV-2-probe, 7 μl extracted DNA and molecular grade water to give final reaction volume of 20 μl.
				HSV-reverse: 5'-ATGTTGTACCCGGTCACGAACT	
				HSV1-probe: 5'-FAM-CATGACCCTTGTGAAACA-MGB	
				HSV-2-probe: 5'-VIC-TGACCTTCGTCAAGCAG-MGB	
doi:10.1371/journal.	.pone.0097259.t001				

May 2014 | Volume 9 | Issue 5 | e97259



Figure 1. Flow diagram of study case and control participant. doi:10.1371/journal.pone.0097259.g001

contrast, real-time PCR techniques need less blood (<500 ul) and can detect the presence of non-viable bacteria. Additionally, realtime PCR assays are semi-quantitative, facilitating differentiation of clinically significant results from contamination.

Despite being a potentially useful adjunct to culture, real-time PCR for the diagnosis of typical sepsis pathogens from blood in any group is not frequently reported in the literature. The majority of studies using molecular techniques to diagnose bloodstream infections in neonates have focused on broad-range bacterial PCR assays, mainly those targeting 16 S rDNA [7]. However, despite the ability of such assays to detect a wide range of bacterial species their sensitivity is limited by ubiquitous contamination of PCR reagents with bacterial DNA [8,9]. Well-designed and optimized species-specific real-time PCR assays offer 100-fold greater sensitivity [10].

Our aim was to develop a novel panel of species-specific realtime PCR assays to identify bloodstream pathogens in term infants with NE in Uganda and to compare the prevalence of pathogenic bacterial species between encephalopathic infants and unaffected controls.

Methods

Ethics Statement

London School of Hygiene & Tropical Medicine, Uganda Virus Research Institute (UVRI) and the Uganda National Council on Science and Technology ethics committees approved the study. Informed written parental consent was taken for all study participants.

Infants were recruited to a larger epidemiological study examining perinatal risk factors for NE in Uganda (the 'ABAaNA study') September 2011 through October 2012. Infants were recruited at Mulago Hospital, Kampala, Uganda's National Referral Hospital. Participants were in-born term infants, <12 hours of age. Cases were infants with NE defined according to the Thompson clinical scoring system [11] with case infants scoring ≥ 6 and controls ≤ 3 . Concurrently recruited unmatched controls were randomly selected from labor ward admissions. Exclusion criteria included living >20 km radius of Mulago Hospital, neonatal intravenous antibiotics administered prior to recruitment and parental consent declined.

Aseptic non-touch venepuncture was performed by trained clinical study staff: 0.5 ml blood (EDTA microfuge tube) for

Characteristic	Case	Control	P-value ^a
	N(%)	N(%)	
Maternal			
Maternal education≤primary level	79/202 (39.1)	45/100 (45.0)	0.327
Nulliparity	118/202 (58.4)	49/101 (48.5)	0.102
Emergency caesarean section	49/201(24.4)	23/101(22.8)	0.757
Intrapartum antibiotics	37/201 (18.4)	16/101 (15.8)	0.580
Neonatal			
Male sex	132/202 (65.4)	48/101 (47.5)	0.003
Mean birth weight (g)	3183	3033	0.0061
1 minute APGAR <3	65/195 (33.3)	1/99 (1)	<0.0001
5 minute APGAR <7	126/177 (71.2)	1/98 (1)	< 0.0001
Case fatality	68/200(34.0)	0/96 (0.0)	< 0.0001

Table 2. Baseline demographic and clinical characteristics of mothers and babies.

^achi-squared test.

doi:10.1371/journal.pone.0097259.t002

Table 3. Comparison of species specific bacterial qPCR and BACTEC blood culture for detection of pathogenic bacteria in blood samples amongst neonatal encephalopathy case infants.

	Blood Culture		
	Positive	Negative	
PCR Positive	3	11	14
PCR Negative	4	184	188
	7	195	202

doi:10.1371/journal.pone.0097259.t003

Table 4. Results of blood culture, real-time PCR assays and sequencing of positives.

Patient	Blood culture	PCR	Sequence	Intrapartum antibiotics	CRP	CRP
					Day 1	Day 3
GROUP B STREPT	ococcus					
Case 61	Coagulase Negative Staphylococcus	Group B Streptococcus	-	Yes	16.86	50.4
Case 81	Negative	Group B Streptococcus	-	No	47.52	Died D1
Case 170	Negative	Group B Streptococcus	-	No	4.23	Died D1
OTHER STREPTOC	COCCUS					
Case 133	Negative	Group A Streptococcus	-	No	61.16	Died D1
Case 150	Group C Streptococcus	Negative	-	No	0.28	1.02
STAPHYLOCOCCU	JS AUREUS					
Case 37	S. aureus	Negative	-	No	6.22	4.03
Case 83	Negative	S. aureus	-	No	2.28	30.4
Case 157	S. aureus	Negative	-	Yes	81.55	63.06
Case 166	S. aureus	Negative	-	No	8.18	20.41
Control 5	Not performed	S. aureus	-	No	55.56	n/a
GRAM NEGATIVE	ORGANISMS					
Case 41	Negative	Enterobacteriaceae	Enterobacter sp.	No	7.58	insuff
Case 53	E.Coli	Enterobacteriaceae	E.coli or Klebsiella sp.	No	1.1	Died D1
Case 56	Negative	Enterobacteriaceae	Failed	No	0.47	Died D1
Case 64	Negative	Enterobacteriaceae	Failed	No	0.22	13.16
Case 67	Negative	Enterobacteriaceae	Enterobacter sp.	No	0.14	Died D1
Case 82	Negative	Enterobacteriaceae	Pantoea sp.	No	8.91	Died D1
Case 117	Negative	Enterobacteriaceae	E.Coli	Yes	32.81	Died D1
MULTIPLE ORGAN	IISMS					
Case 132	S. aureus	S. aureus	-	No	49.01	-
		Enterobacteriaceae	E.Coli			
		Cytomegalovirus	-			
Case 49	Klebsiella sp.	Enterobacteriaceae	Klebsiella sp.	Yes	3.61	9.32
		P. falciparum	-			
Control 65	Not performed	Enterobacteriaceae	E.Coli	No	1.83	n/a
		S. pneumoniae	-			
VIRUSES & MALA	RIA					
Case 10	Negative	Cytomegalovirus	-	n/a	2.68	Died D1
Case 16	Negative	Cytomegalovirus	-	n/a	0.16	Died D1
Control 21	Not perform	Cytomegalovirus	-	n/a	0.32	n/a
Case 175	Negative	Herpes Simplex Virus 1	-	n/a	0.35	2.79
Control 98	Not performed	P. falciparum	-	n/a	1.38	n/a

doi:10.1371/journal.pone.0097259.t004

quantitative PCR (all infants), 0.5–1.0 ml whole blood inoculated into a single pediatric blood culture (BC) bottle (BACTEC Peds Plus, Becton Dickinson, Sparks MD; all cases and control infants clinically unwell on assessment), and 0.5 ml (serum microfuge tube) for C-reactive protein (CRP) (all infants, COBAS, Roche Diagnostics). A repeat sample for CRP was taken after 48 hours amongst surviving cases. Culture bottles were loaded into the Bactec 9240 automated instrument at the MRC/UVRI microbiology laboratory. Gram-stained, subcultured, and purified colonies were manually identified from positive cultures.

Bead-beating of EDTA-blood samples (300 μ l) was performed to ensure complete lysis of bacterial cells. DNA (200 μ l elute) was extracted using the QiAmp DNA blood mini kit and a QIAcube semi-automated extraction platform (both Qiagen, Manchester, UK). Each batch (12 samples) included a negative extraction control (200 μ l of buffer AE, Qiagen). CT and PN performed all DNA extraction in the MRC/UVRI virology laboratories.

Ten targets and an internal control were amplified in five separate multiplexed reactions (Table 1) on a 7500 Fast Real Time PCR system (Life Technologies, Paisley, UK). Cycling conditions were 95°C for 5 minutes then 45 cycles of 95°C for 30 seconds and 60°C for 30 seconds. A positive result was any target detected with a cycle-threshold (CT) value <38. A no template control was included for each multiplexed assay. A positive control was included for every target organism. For bacterial targets this was DNA extracted from suspensions of cultured laboratory strains of known provenance, for viral targets this was plasmid DNA and for Plasmodium falciparum this was a microscopically positive clinical sample. A valid run required detection of each positive control with a CT value within a set range (normally 28.5-31.5). For bacterial assays suspensions of control organisms were quantified using a plate-counting method and for viral assays plasmid DNA was quantified using the NanoDrop Spectrophotometer (Labtech, Uckfield, UK). PCR assays were performed in the laboratories of UVRI and Great Ormond Street Hospital (GOSH), by CT and KH. Clinical staff and technicians were not blinded to case control status. Blood culture results were not available to staff prior to performing PCR assays.

Enterobacteriaceae PCR positives were further identified by amplicon sequencing using Big-Dye 3.1 Cycle-sequencing kit (Life Technologies) and analyzed on a 3130 Genetic Analyse (Life Technologies). Sequences were compared to an in-house database of Enterobacteriaceae *dnaK* sequences using MegAlign (Lasergene 10, DNAStar, Madison, WI, USA) or by BLAST searching against the Genbank database (http://www.ncbi.nlm.nih.gov).

The prevalence of bacteremia between cases and controls was compared using the Chi-squared test using STATA version 12.0.

Results

Samples from 202 case and 101 controls were examined (Figure 1). Most encephalopathic infants were moderately or severely affected (89.1%, n = 180). Compared to controls they were more likely to be male, have abnormal APGAR scores at one and five minutes, and have a higher mean birth weight (Table 2). Intrapartum antibiotic use was similar.

Comparison of Bacterial PCR and Culture Results amongst Infants with NE vs. Controls

The prevalence of neonatal bacteremia with a pathogenic organism amongst encephalopathic infants was 3.5% (7) by BC alone, 6.9% (14) by PCR alone and 8.9% (18) by BC and PCR in combination (Table 3). Of the 101 control infants, none was positive for pathogenic bacterial species on BC but two were

positive on PCR, giving a prevalence of neonatal bacteremia amongst the control group of 2.0% (2/101). Four control infants were clinically unwell on recruitment, so BCs were performed in addition to PCR; all 4 were negative on both tests. The prevalence of bacteremia (by either BC or PCR) was significantly higher amongst infants with encephalopathy than those without (8.9% vs. 2.0% respectively, p-value = 0.028). Coagulase negative staphylococcus (CoNS), usually considered non-pathogenic amongst term newborns, was more commonly found on PCR amongst controls compared to cases, but this difference was not statistically significant (9.9% (9/101) in controls vs. 5.5% (11/202) in cases, p = 0.252).

Case Infants with Positive Blood-cultures

Seven case infants had a positive BC, four of these (3 *Staphylococcus aureus* and 1 Group C Streptococcus) were PCR negative. The other three cases also yielded a positive PCR result; one *E. coli* by both methods, a second *S. aureus* by both methods but also PCR positive for the Enterobacteriaceae target and a third case was BC positive for CoNS but PCR positive for Group B Streptococcus (GBS) (Table 4).

Cases with Negative Blood-cultures

One hundred and ninety five case infants had negative BCs, 184 of these were also negative by PCR.

The remaining 11 BC negative cases were positive by real-time PCR for a bacterial target (3 GBS, 1 Group A Streptococcus (GAS), 1 *S. aureus* and 6 Enterobacteriaceae). Of the five infants PCR positive, BC negative for pathogenic streptococcal or staphylococcal species, four had substantially raised CRP levels on day 1 or day 3 and the fifth (case 170) died <24 hours after a clinical course consistent with aggressive GBS septicemia with persistent hyperthermia, severe respiratory distress and seizures. Sequencing of the Enterobacteriaceae amplicon in the 6 positive cases allowed identification of a pathogenic organism (at least to genus level) in 4 cases (2 *Enterobacter sp.*, 1 *Pantoea sp.* and 1 *E. coli*) but was unsuccessful in 2 cases therefore these are identified only as Enterobacteriaceae (Table 4).

In the absence of normative CRP data for this population, a raised CRP was defined as CRP>97th centile amongst controls (=40.7 mg/L). Of case infants without evidence of bacteremia on PCR or BC, 5.0% (9/181) had a raised CRP on day one, rising to 16.2% (19/117) on day 3 amongst survivors. Bacteraemic case infants were significantly more likely to have a raised CRP on day one compared to non-bacteraemic infants (22.2% (4/18) vs. 5.0% (9/181), p = 0.005).

Cytomegalovirus, Herpes Simplex & Malaria

The prevalence of cytomegalovirus (CMV) infection was 1.5% (3/202) amongst cases and 1.0% (1/101) in controls. Herpes simplex virus (HSV) was identified in one case infant (0.5%) and *P. falciparum* in one case and one control infant.

Discussion

The accurate diagnosis of infectious co-morbidity in the unwell newborn through clinical signs or standard culture techniques is problematic [12]. Our novel panel of multiplexed real-time PCR assays, designed to cover the majority of common pathogens implicated in congenital neonatal infections, was successful in detecting more bacteremia than culture alone amongst encephalopathic Ugandan newborns. A significantly higher prevalence of potentially pathogenic bacterial species was seen in encephalopathic babies when compared to controls suggesting that fetal exposure to bacterial blood-borne pathogens may be a causal factor for neonatal encephalopathy in this setting. This may be mediated by cytokines and inflammatory cells which have been found to be intermediaries in perinatal brain injury secondary to hypoxia-ischemia, neurotoxins and infection [13] or by enhanced sensitivity of the brain to hypoxia-ischemia after exposure to bacterial products such as endotoxin³.

Eleven culture-negative encephalopathic infants tested positive on bacterial PCR for pathogenic organisms. Amongst these, two organisms could only be identified and as Enterobacteriaceae and as this family contains environmental non-pathogenic species, interpretation of these two PCR positives is uncertain. Coagulase negative staphylococcus, considered non-pathogenic in the absence of indwelling catheters, was common amongst both case and control infants. Open venepuncture may have contributed to an increased contamination risk. False positive PCR results due to laboratory contamination are unlikely since negative controls were consistently negative and strict laboratory practice was followed to prevent contamination.

The prevalence of congenital cytomegalovirus (CMV) is thought to be high in low income settings (1-5%) where it is commonly secondary to non-primary maternal infections [14]. No Ugandan studies have published rates of congenital CMV infection. Our prevalence of 1% amongst controls is substantially lower than that reported from a recent birth cohort in the Gambia (5.4%) [15]. Our prevalence of congenital CMV was similar between encephalopathic and non-encephalopathic infants suggesting that CMV does not contribute to the burden of neonatal encephalopathy in this setting. Herpes Simplex and *P. falciparum* infections were similarly uncommon.

There are limitations of all laboratory techniques utilized in the detection of bacteremia. In our study, important pathogens such as GBS, *S. aureus* and Enterobacteriaceae were detected by PCR but not culture; however bacteremia in four infants was detected by culture alone. This was most common for *S. aureus*, a robust organism that grows well in the laboratory hence culture may be

References

- Eklind S, Mallard C, Leverin AL, Gilland E, Biomgren K, et al. (2001) Bacterial endotoxin sensitizes the immature brain to hypoxic-ischaemic injury. Eur.J Neurosci 13: 1101–1106.
- Mallard C, Welin AK, Peebles D, Hagberg H, Kjellmer I (2003) White matter injury following systemic endotoxemia or asphyxia in the fetal sheep. Neurochem Res 28: 215–223.
- Eklind S, Mallard C, Arvidsson P, Hagberg H (2005) Lipopolysaccharide induces both a primary and a secondary phase of sensitization in the developing rat brain. Pediatric Research 58: 112–116.
- Mallard C (2012) Innate immune regulation by Toll-like receptors in the brain. ISRN Neurology 2012: 19.
- Stridh L, Mottahedin A, Johansson ME, Valdez RC, Northington F, et al. (2013) Toll-like receptor-3 increases the vulnerability of the neonatal brain to hypoxiaischaemia. Journal of Neuroscience 33: 12041–12051.
- 6. Peebles D (2007) Intrauterine infection and perinatal brain injury. 1–7 p.
- Pammi M, Flores A, Leeflang M, Versalovic J (2011) Molecular assays in the diagnosis of neonatal sepsis: A systematic review and meta-analysis. Pediatrics 128: e973–e985.
- Harris KA, Hartley JC (2003) Development of broad-range 16 s rDNA PCR for use in the routine diagnostic clinical microbiology service Journal of Medical Microbiology 5: 685–691.

more sensitive than PCR for detecting low levels of *S. aureus* bacteremia in these infants. Even a combination of PCR and culture is unlikely to exclude all infants with early sepsis, highlighted by the substantial number of culture negative/PCR negative infants with a substantially raised CRP on either day one or day 3. This emphasizes the importance of empirical antibiotic therapy to all sick newborns including those with NE. In addition, PCR assays offer no information on antimicrobial susceptibility, and contamination with commensal and environmental organisms remains an issue for all techniques.

In conclusion, we have found high levels of bacteremia in infants with NE in an African setting using a combination of blood culture and species-specific real-time PCR assays to identify bloodstream pathogens. Significantly more encephalopathic infants than controls had pathogenic bacterial species detected suggesting that neonatal bacteremia may be an important risk factor for NE in this setting. Our real-time PCR panel detected more bacteremia than culture alone and provides a novel tool for detection of neonatal bloodstream pathogens that could be applied across a range of clinical situations and settings.

Acknowledgments

We would like to acknowledge the contribution of the maternity and neonatal staff at Mulago Hospital for their assistance in recruiting of study infants, the National Influenza Centre at the Uganda Virus Research Institute and the Virology department at the MRC/UVRI Ugandan Research Unit on AIDS who provided essential laboratory facilities to perform the PCR assays. Thanks also to the families who participated in the ABAaNA study.

Author Contributions

Conceived and designed the experiments: CJT KAH NK NJR AME JJK. Performed the experiments: CJT PN KAH JO JW. Analyzed the data: CJT KAH BAW NK. Contributed reagents/materials/analysis tools: KAH NK CJT AME PH. Wrote the paper: CJT KAH NJR NK AME JJK BAW. Participant recruitment and data collection: NN MN.

- Corless CE, Guiver M, Borrow R, Edwards-Jones V, Kaczmarski EB, et al. (2000) Contamination and sensitivity issues with a real-time universal 16S rRNA PCR. Journal of Clinical Microbiology 38: 1747–1752.
- Harris KA, Turner P, Green EA, Hartley JC (2008) A duplex real-time PCR assay for the detection, and determination of penicillin susceptibility, of *Streptococcus pneumoniae* in clinical samples Journal of Clinical Microbiology 46: 2751–2758.
- Thompson CM, Puterman AS, Linley LL, Hann FM, van der Elst CW, et al. (1997) The value of a scoring system for hypoxic ischaemic encephalopathy in predicting neurodevelopmental outcome. Acta Paediatr 86: 757–761.
- 12. Edmond K, Zaidi A (2010) New approaches to preventing, diagnosing, and treating neonatal sepsis. Plos Medicine 7: e1000213.
- McAdams R, Juul S (2012) The role of cytokines and inflammatory cells in perinatal brain injury. Neurology Research International: 15 pages.
- Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK (2013) The "Silent" Global Burden of Congenital Cytomegalovirus. Clinical Microbiology Reviews 26: 86–102.
- van der Sande MAB, Kaye S, Miles DJC, Waight P, Jefferies DJ, et al. (2007) Risk factors for and Clinical Outcome of Congenital Cytomegalovirus Infection in a Peri-Urban West-African Birth Cohort. Plos ONE 2: e492.